WO2014186704A3 - Novel compounds for the treatment of cystic fibrosis - Google Patents

Novel compounds for the treatment of cystic fibrosis Download PDF

Info

Publication number
WO2014186704A3
WO2014186704A3 PCT/US2014/038385 US2014038385W WO2014186704A3 WO 2014186704 A3 WO2014186704 A3 WO 2014186704A3 US 2014038385 W US2014038385 W US 2014038385W WO 2014186704 A3 WO2014186704 A3 WO 2014186704A3
Authority
WO
WIPO (PCT)
Prior art keywords
cystic fibrosis
compounds
novel compounds
treatment
methods
Prior art date
Application number
PCT/US2014/038385
Other languages
French (fr)
Other versions
WO2014186704A2 (en
Inventor
Xicheng Sun
Jian Qiu
Adam Stout
Original Assignee
N30 Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N30 Pharmaceuticals, Inc. filed Critical N30 Pharmaceuticals, Inc.
Publication of WO2014186704A2 publication Critical patent/WO2014186704A2/en
Publication of WO2014186704A3 publication Critical patent/WO2014186704A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to novel compounds, pharmaceutical compositions comprising such compounds, and the methods of making and using the same. These compounds are useful as modulators of Cystic Fibrosis Transmembrane Conductor Regulator (CFTR). The present invention also relates to methods of treating or lessening the severity of cystic fibrosis in a patient. These compounds may be used alone or in combination with one or more secondary active agents.
PCT/US2014/038385 2013-05-17 2014-05-16 Novel compounds for the treatment of cystic fibrosis WO2014186704A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361824813P 2013-05-17 2013-05-17
US61/824,813 2013-05-17

Publications (2)

Publication Number Publication Date
WO2014186704A2 WO2014186704A2 (en) 2014-11-20
WO2014186704A3 true WO2014186704A3 (en) 2015-01-29

Family

ID=51899018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/038385 WO2014186704A2 (en) 2013-05-17 2014-05-16 Novel compounds for the treatment of cystic fibrosis

Country Status (1)

Country Link
WO (1) WO2014186704A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5409010B2 (en) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Solid form of N- [2,4-bis (1,1-dimethylethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2016057730A1 (en) 2014-10-07 2016-04-14 Strohmeier Mark Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US20170281612A1 (en) * 2014-10-08 2017-10-05 Nivalis Therapeutics, Inc. Methods for the Treatment of Cystic Fibrosis
CN106008276B (en) * 2016-05-20 2018-07-06 湖北出入境检验检疫局检验检疫技术中心 The synthetic method of the phenylurea analog herbicide of phenylurea analog herbicide or deuterated label
KR20220100625A (en) 2019-11-12 2022-07-15 젠자임 코포레이션 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
CN112546039A (en) * 2020-12-18 2021-03-26 北京大学 Application of apigenin in preparation of medicine for treating and/or preventing autosomal dominant hereditary polycystic kidney disease
WO2023034946A1 (en) 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and uses thereof in the treatement of cystic fibrosis
AU2022340880A1 (en) 2021-09-03 2024-03-07 Genzyme Corporation Indole compounds and methods of use
WO2024054840A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocyclic compounds, compositions, and methods of using thereof
WO2024054845A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocycic compounds, compositions, and methods of using thereof
WO2024054851A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocyclic compounds, compositions and methods of using thereof
WO2024072793A1 (en) * 2022-09-26 2024-04-04 Rectify Pharmaceuticals, Inc. Pyridine carboxamide compounds and their use in treating medical conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210638A1 (en) * 2005-11-08 2010-08-19 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2011101805A1 (en) * 2010-02-18 2011-08-25 Genkyotex Sa Pyrazolo piperidine derivatives as nadph oxidase inhibitors
US20120071461A1 (en) * 2010-09-22 2012-03-22 Gruenenthal Gmbh Substituted Benzamide Compounds
US20130079412A1 (en) * 2011-04-13 2013-03-28 Bayer Pharma Aktiengesellschaft Branched 3-phenylpropionic acid derivatives and their use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210638A1 (en) * 2005-11-08 2010-08-19 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2011101805A1 (en) * 2010-02-18 2011-08-25 Genkyotex Sa Pyrazolo piperidine derivatives as nadph oxidase inhibitors
US20120071461A1 (en) * 2010-09-22 2012-03-22 Gruenenthal Gmbh Substituted Benzamide Compounds
US20130079412A1 (en) * 2011-04-13 2013-03-28 Bayer Pharma Aktiengesellschaft Branched 3-phenylpropionic acid derivatives and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAYDAR ET AL.: "The pyrethrins and related compounds. Part XXXIII. Effective combinations in the gemdimethyl-central group region of non-ester pyrethroids;", PESTICIDE SCIENCE, vol. 23, no. ISSUE, 28 April 2006 (2006-04-28), pages 231 - 246, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/doi/10.1002/ps.2780230305/abstract> [retrieved on 20141201] *
BEFETUPITANT: "IUPAC: 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6- morpholin-4-ylpyridin-3-yl]propanamide;CID 6450815;", 29 April 2006 (2006-04-29), Retrieved from the Internet <URL:http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6450815> *

Also Published As

Publication number Publication date
WO2014186704A2 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
WO2014186704A3 (en) Novel compounds for the treatment of cystic fibrosis
PH12017502297A1 (en) Antibacterial compounds
MX2018015656A (en) Heterocyclic compounds as antibacterials.
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
EP3038661A4 (en) Methods and compositions for rna-guided treatment of hiv infection
WO2011140202A3 (en) Mif modulators
PH12015501738A1 (en) Androgen receptor modulators and uses thereof
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
MX2015001250A (en) Compositions and treatment for eye diseases and disorders.
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
CA2900779C (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
MX2016013826A (en) Peroxide formulations and methods and applicators for using the same.
CA2902795C (en) Glycopyrrolate salts
MX2013003309A (en) Substituted benzamide compounds.
MX356755B (en) Fumigillol type compounds and methods of making and using same.
WO2013123249A3 (en) Formulations and methods for treating ear conditions
WO2014121137A3 (en) Compositions and methods for the treatment of neurodegenerative and other diseases
AU2014233420A8 (en) Fine dry particulate retinoid active agent compositions and topical formulations including the same
MX2015000179A (en) Itraconazole compositions and dosage forms, and methods of using the same.
HK1210417A1 (en) Compositions, methods and/or devices for prevention and/or treatment of dry eye disorders //
MX2016004078A (en) Hiv treatment formulation of atazanavir and cobicistat.
EP3068316A4 (en) Devices, kits and methods relating to treatment of facet joints
WO2014167428A3 (en) Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
WO2013057592A3 (en) Treatment of sickle cell disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14797298

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14797298

Country of ref document: EP

Kind code of ref document: A2